EpilepsyPhase 3NCT00050934
Pediatric Epilepsy Study
A Phase 3 study testing oxcarbazepine in people with Epilepsy and Epilepsies, Partial, run by Novartis Pharmaceuticals at 30 sites in 4 countries.
Trial summary
This study will evaluate the safety and effectiveness of oxcarbazepine (Trileptal) as add-on therapy in the treatment of partial seizures in pediatric patients 1 month to 3 years of age. Read more about this study
- Who is it for?
- Ages 1 month to 3 years
- Conditions the study is for
- Epilepsy, Epilepsies, Partial
- What is being tested?
- oxcarbazepine
- How many people
- 132 participants
- Where
- 30 sitesin 4 countries
- Study dates
- Jun 2002to Jun 2004
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 month to 3 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Have a diagnosis of partial seizures
- Be willing to be hospitalized
- Weigh a minimum of 6.6 pounds
- Be taking a stable dose of one to two concomitant anti-epileptic medications
- Have had a previous CAT scan/MRI confirming the absence of space occupying lesions or progressive neurological disease
- Have normal laboratory results
Show all 20Show fewer
- EXCLUSION CRITERIA: To enter this study, a patient must not have or be:
- Seizures caused by metabolic disturbance, toxic exposure, or active infection
- A primary diagnosis of generalized epilepsy (exception - secondarily generalized seizures)
- A history of status epilepticus within 30 days
- Seizures not related to epilepsy
- Frequent use of additional anti-epileptic medications to treat increases in seizures (for example: rectal diazepam)
- Taking felbamate within 6 months
- Serum sodium levels <135 mEq/L
- Significant heart, breathing, kidney, stomach, liver, blood, or cancer disorder requiring treatment/therapy
- A history of chronic infection (e.g., hepatitis or HIV)
- Significant electrocardiogram (ECG) abnormalities
- A nursing mother taking anti-convulsant drugs
- Previously demonstrated sensitivity/allergic reaction to Trileptal or related compounds
- Used experimental medication within 30 days of entering this study
Who cannot join
None listed.
Trial locations and contacts
30 sites in 4 countries.
30 sites in 4 countries
United States26 sites
Study site
Akron, Ohio, 44308
Study site
Ann Arbor, Michigan, 48109
Study site
Atlanta, Georgia, 30342
Study site
Birmingham, Alabama, 35233
Study site
Boise, Idaho, 83712
Study site
Buffalo, New York, 14222
Study site
Chesterfields, Missouri, 63017
Study site
Cincinnati, Ohio, 45229
Study site
Cleveland, Ohio, 44106
Study site
Duluth, Minnesota, 55805
Study site
Fort Worth, Texas, 76104
Study site
Houston, Texas, 77030
Study site
Los Angeles, California, 90027
Study site
Los Angeles, California, 90095
Study site
Madera, California, 93638
Study site
Miami, Florida, 33155
Study site
Mobile, Alabama, 36693
Study site
New York, New York, 10016
Study site
New York, New York, 10032
Study site
Norfolk, Virginia, 23507
Study site
Orange, California, 92868
Study site
Philadelphia, Pennsylvania, 19104
Study site
Portland, Oregon, 97201
Study site
Saint Paul, Minnesota, 55102
Study site
Tampa, Florida, 33607
Study site
Wilmington, Delaware, 19806
About this study
Official title: A Multicenter, Rater-blind, Randomized, Age-stratified, Parallel-group Study Comparing Two Doses of Oxcarbazepine as Adjunctive Therapy in Pediatric Patients With Inadequately-controlled Partial Seizures.
This study will evaluate the safety and effectiveness of oxcarbazepine (Trileptal) as add-on therapy in the treatment of partial seizures in pediatric patients 1 month to 3 years of age.
- Conditions
- Epilepsy, Epilepsies, Partial
- Being tested
- oxcarbazepine
- Keywords
- partial seizures
- Medical subject headings
- Epilepsy, Epilepsies, Partial, Seizures
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
oxcarbazepineDrug
What is being measured
The primary outcome is the main question the study is designed to answer.
change in seizure frequency/24 hours (during the last 72 hours in the Treatment Phase compared to Baseline)
Secondary outcomes (1)
% change in seizure frequency/24 hours; change in seizure frequency/24 hours; response to treatment (at least a 50%, 75%, or 100% reduction seizure frequency/24 hours).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Jan 2003 (estimated)
- Study startJun 2002
- Primary completionJun 2004
- Study completionJun 2004
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for EpilepsyStudies of the same condition, open and under way.
- More trials run by Novartis PharmaceuticalsThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Enrolment
- 132 participants (actual)
Sponsor and investigators
- Lead sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Novartis Pharmaceuticals, Study director, Novartis Pharmaceuticals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00050934
- Sponsor's protocol ID
- CTRI476E 2340
- Status last verified
- Nov 2011
- First submitted
- 30 Dec 2002
- Last updated
- 23 Nov 2011
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Nov 2011. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter, Rater-blind, Randomized, Age-stratified, Parallel-group Study Comparing Two Doses of Oxcarbazepine as Adjunctive Therapy in Pediatric Patients With Inadequately-controlled Partial Seizures.
- ClinicalTrials.gov ID
- NCT00050934
- Acronym / sponsor ID
- CTRI476E 2340
- Conditions
- Epilepsy, Epilepsies, Partial
- Keywords
- partial seizures
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 132 participants (actual)
- Lead sponsor
- Novartis PharmaceuticalsIndustry (pharma, biotech, devices)
- Study start
- Jun 2002
- Primary completion
- Jun 2004 (actual)
- Study completion
- Jun 2004 (actual)
- First posted
- 1 Jan 2003 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will evaluate the safety and effectiveness of oxcarbazepine (Trileptal) as add-on therapy in the treatment of partial seizures in pediatric patients 1 month to 3 years of age.
Study design
- Primary purpose
- Treatment
Who may qualify
- Ages
- 1 month to 3 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (20 listed)
- Have a diagnosis of partial seizures
- Be willing to be hospitalized
- Weigh a minimum of 6.6 pounds
- Be taking a stable dose of one to two concomitant anti-epileptic medications
- Have had a previous CAT scan/MRI confirming the absence of space occupying lesions or progressive neurological disease
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| oxcarbazepine | Drug | – |
Primary outcome
change in seizure frequency/24 hours (during the last 72 hours in the Treatment Phase compared to Baseline)
1 secondary outcome
% change in seizure frequency/24 hours; change in seizure frequency/24 hours; response to treatment (at least a 50%, 75%, or 100% reduction seizure frequency/24 hours).
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Nov 2011.
Related trials for Epilepsy
Enrolling by invitationObservational study
Study of Direct Brain Recording and Stimulation for Memory Enhancement
Epilepsy
RecruitingObservational study
Epilepsy Seizure Detection With Innovative Tripolar EEG (tEEG)
Epilepsy
Not yet recruiting
Biomarker Targeted Stimulation for Epileptiform Events
Epilepsy
Active, not recruitingPhase 3
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
Dravet Syndrome
Enrolling by invitationPhase 2
SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures
Focal Onset Seizures
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Novartis Pharmaceuticals study director
Novartis Pharmaceuticals
30 sites in 4 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing oxcarbazepine in people with Epilepsy and Epilepsies, Partial, run by Novartis Pharmaceuticals at 30 sites in 4 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 20 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Nov 2011. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 30 sites in United States, Germany, Brazil, Mexico. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
change in seizure frequency/24 hours (during the last 72 hours in the Treatment Phase compared to Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Nov 2011; AzTrials last refreshed its copy on 28 Oct 2026.